Literature DB >> 8543627

Immunohistochemistry in apparently normal bone marrow trephine specimens from patients with nodal follicular lymphoma.

R Chetty1, G Echezarreta, M Comley, K Gatter.   

Abstract

AIM: To establish the role of immunohistochemistry (using a limited panel of antibodies) in detecting minimal involvement by follicular lymphoma in routinely processed bone marrow trephine specimens, which show no obvious morphological (light microscopic) evidence of lymphoma; to determine whether bcl-2 immunostaining in bone marrow distinguishes between benign and malignant infiltrates in a patient with nodal follicular lymphoma.
METHODS: Twenty seven consecutively selected paraffin wax embedded, formalin fixed bone marrow trephine specimens were stained with the following antibodies: anti-bcl-2, anti-CD79a, anti-CD3, and kappa and lambda light chains, using the Streptavidin biotin complex technique.
RESULTS: Five of the 27 cases, which showed no evidence of involvement by follicular lymphoma on routine stains, showed monotypic B cells on immunohistochemistry. Two of the cases were diffuse, while the remaining three showed mini-aggregates around bony trabeculae. In all five cases the lymphomatous infiltrates were strongly bcl-2 positive. Reactive B lymphoid nodules did not show the same degree of bcl-2 positivity, and negative cells could be discerned within the reactive nodules.
CONCLUSIONS: There is merit in studying so-called negative bone marrows immunohistochemically in order to detect minimal involvement by follicular lymphoma. A limited panel of antibodies including anti-bcl-2, anti-CD79a and anti-CD3 is usually adequate to accomplish this. Strongly bcl-2 positive lymphoid aggregates in the bone marrow of patients with nodal follicular lymphoma are indicative of lymphoma.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8543627      PMCID: PMC503010          DOI: 10.1136/jcp.48.11.1035

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  7 in total

1.  Immunoarchitecture of normal human bone marrow: a study of frozen and fixed tissue sections.

Authors:  S S Shin; K Sheibani; J Kezirian; A Nademanee; S J Forman; S K Lee; C D Winberg
Journal:  Hum Pathol       Date:  1992-06       Impact factor: 3.466

2.  Immunohistochemistry in bone marrow diagnosis. Value of a panel of monoclonal antibodies on routinely processed bone marrow biopsies.

Authors:  P van der Valk; H Mullink; P C Huijgens; T M Tadema; W Vos; C J Meijer
Journal:  Am J Surg Pathol       Date:  1989-02       Impact factor: 6.394

3.  Lymphocyte subsets in normal bone marrow.

Authors:  P Clark; D E Normansell; D J Innes; C E Hess
Journal:  Blood       Date:  1986-06       Impact factor: 22.113

4.  Lymphoid nodules of bone marrow: normal and abnormal.

Authors:  A M Rywlin; R S Ortega; C J Dominguez
Journal:  Blood       Date:  1974-03       Impact factor: 22.113

Review 5.  Detection of minimal residual disease in acute leukemia by immunological marker analysis and polymerase chain reaction.

Authors:  J J van Dongen; T M Breit; H J Adriaansen; A Beishuizen; H Hooijkaas
Journal:  Leukemia       Date:  1992       Impact factor: 11.528

6.  tal-1 deletions in T-cell acute lymphoblastic leukemia as PCR target for detection of minimal residual disease.

Authors:  T M Breit; A Beishuizen; W D Ludwig; E J Mol; H J Adriaansen; E R van Wering; J J van Dongen
Journal:  Leukemia       Date:  1993-12       Impact factor: 11.528

Review 7.  Bone marrow manifestations of malignant lymphoma and lymphoma-like conditions.

Authors:  R D Brunning; R W McKenna
Journal:  Pathol Annu       Date:  1979
  7 in total
  2 in total

1.  Bcl-2 protein does not help to distinguish benign from malignant lymphoid nodules in bone marrow biopsy specimens.

Authors:  A Skálová; F Fakan
Journal:  J Clin Pathol       Date:  1997-01       Impact factor: 3.411

2.  Routine use of ancillary investigations in staging diffuse large B-cell lymphoma improves the International Prognostic Index (IPI).

Authors:  Dipti Talaulikar; Bruce Shadbolt; Jane E Dahlstrom; Anne McDonald
Journal:  J Hematol Oncol       Date:  2009-11-22       Impact factor: 17.388

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.